Your browser doesn't support javascript.
loading
HCT frailty scale for younger and older adults undergoing allogeneic hematopoietic cell transplantation.
Salas, Maria Queralt; Atenafu, Eshetu G; Pasic, Ivan; Bascom, Ora; Wilson, Leeann; Lam, Wilson; Law, Arjun Datt; Chen, Carol; Novitzky-Basso, Igor; Kim, Dennis Dong Hwan; Gerbitz, Armin; Viswabandya, Auro; Michelis, Fotios V; Lipton, Jeffrey Howard; Mattsson, Jonas; Alibhai, Shabbir M H; Kumar, Rajat.
Affiliation
  • Salas MQ; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.
  • Atenafu EG; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Pasic I; HCT Unit, Hospital Clinic de Barcelona, ICHMO, Barcelona, Spain.
  • Bascom O; Department of Biostatistics, Princes Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Wilson L; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.
  • Lam W; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Law AD; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Chen C; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Novitzky-Basso I; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.
  • Kim DDH; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Gerbitz A; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.
  • Viswabandya A; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Michelis FV; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.
  • Lipton JH; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Mattsson J; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.
  • Alibhai SMH; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Kumar R; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.
Bone Marrow Transplant ; 58(11): 1237-1246, 2023 11.
Article in En | MEDLINE | ID: mdl-37620424
The HCT Frailty Scale is an easy prognostic tool composed of (a) Clinical Frailty Scale; (b) Instrumental Activities of Daily Living; (c) Timed-up-and-Go test; (d) Grip Strength; (e) Self-Health Rated Questionnaire; (f) Falls tests; (g) Albumin and C-reactive protein levels. This scale was designed to classify allogeneic hematopoietic cell transplant (alloHCT) candidates into fit, pre-frail and frail groups, irrespective of age. This study evaluates the ability of this frailty classification to predict overall survival (OS) and non-relapse mortality (NRM) in adult patients of all ages, in a prospective sample of 298 patients transplanted between 2018 and 2020. At first consultation, 103 (34.6%) patients were fit, 148 (49.7%) pre-frail, and 47 (15.8%) were frail. The 2-year OS and NRM of the three groups were 82.9%, 67.4%, and 48.3% (P < 0.001), and 5.4%, 19.2%, and 37.7% (P < 0.001). For patients younger than 60 years (n = 174), the 2-year OS and NRM of fit, pre-frail, and frail groups were 88.4%, 69.3% and 53.1% (P = 0.002), and 5.8%, 22.8%, and 34.8% (P = 0.005), respectively; and in patients older than 60 (n = 124), OS and NRM were 75.5%, 63.8% and 41.4% (P = 0.006), and 4.9%, 16.4%, and 42.1% (P = 0.001). In conclusion, frailty predicted worse transplant outcomes in both younger and older adults.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation / Frailty Type of study: Prognostic_studies Limits: Aged / Humans Language: En Journal: Bone Marrow Transplant Journal subject: TRANSPLANTE Year: 2023 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation / Frailty Type of study: Prognostic_studies Limits: Aged / Humans Language: En Journal: Bone Marrow Transplant Journal subject: TRANSPLANTE Year: 2023 Document type: Article Affiliation country: Country of publication: